Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,260 | 6 | 87.6% |
| Travel and Lodging | $1,080 | 1 | 11.5% |
| Food and Beverage | $93.60 | 2 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Omeros Corporation | $8,264 | 7 | $0 (2020) |
| CSL Behring | $1,170 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $8,264 | 7 | Omeros Corporation ($8,264) |
| 2018 | $1,170 | 2 | CSL Behring ($1,170) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2020 | Omeros Corporation | Narsoplimab (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: Hematology Oncology | ||||||
| 09/16/2020 | Omeros Corporation | Narsoplimab (Drug) | Consulting Fee | Cash or cash equivalent | $820.00 | General |
| Category: Hematology Oncology | ||||||
| 08/12/2020 | Omeros Corporation | Narsoplimab (Drug) | Consulting Fee | Cash or cash equivalent | $240.00 | General |
| Category: Hematology Oncology | ||||||
| 07/01/2020 | Omeros Corporation | Narsoplimab (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Hematology Oncology | ||||||
| 05/27/2020 | Omeros Corporation | Narsoplimab (Drug) | Consulting Fee | Cash or cash equivalent | $2,900.00 | General |
| Category: Hematology Oncology | ||||||
| 04/28/2020 | Omeros Corporation | Narsoplimab (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Hematology Oncology | ||||||
| 02/13/2020 | Omeros Corporation | Omidria (Drug) | Food and Beverage | Cash or cash equivalent | $3.77 | General |
| Category: Ophthalmology | ||||||
| 04/24/2018 | CSL Behring | — | Travel and Lodging | In-kind items and services | $1,080.44 | General |
| 04/24/2018 | CSL Behring | — | Food and Beverage | In-kind items and services | $89.83 | General |
About Dr. Willam Marks, MD
Dr. Willam Marks, MD is a Transplant Surgery healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942365705.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Willam Marks, MD has received a total of $9,434 in payments from pharmaceutical and medical device companies, with $8,264 received in 2020. These payments were reported across 9 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($8,260).
Practice Information
- Specialty Transplant Surgery
- Location Seattle, WA
- Active Since 12/22/2006
- Last Updated 07/08/2007
- Taxonomy Code 204F00000X
- Entity Type Individual
- NPI Number 1942365705
Products in Payments
- Narsoplimab (Drug) $8,260
- Omidria (Drug) $3.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Transplant Surgery Doctors in Seattle
Dr. Shane Ottmann, Md, MD
Transplant Surgery — Payments: $22,873
Austin Spitzer, Md, MD
Transplant Surgery — Payments: $13,057
Yong Kwon, M.d, M.D
Transplant Surgery — Payments: $5,139
Dr. Phillip Chapman, Md, MD
Transplant Surgery — Payments: $4,880
Dr. Ryutaro Hirose, Md, MD
Transplant Surgery — Payments: $3,728
Julian Horwitz, Md, MD
Transplant Surgery — Payments: $1,823